Factor VIII Activity: Nursing Guide
Factor VIII activity measures the clotting function of Factor VIII, the protein deficient in haemophilia A, as a percentage of normal plasma activity. Nurses protect result validity through correct citrate collection, pre-analytic timing, and safe bleeding precautions — and must distinguish low FVIII from a prolonged aPTT in the full coagulation picture before taking medication or procedure decisions.
Contents
Quick Facts
Key Takeaway
A very low Factor VIII activity confirms haemophilia A severity, but nurses must also watch for prolonged aPTT with normal PT, avoid IM injections and NSAIDs without haematology guidance, and escalate joint
Specimen & Collection Details
Nurse quick-reference for collection prep that affects result quality.
Light blue top
3.2% sodium citrate (9:1 blood-to-anticoagulant ratio)
Platelet-poor plasma (citrated)
Tube filled to completion per coagulation protocol; approximately 1 mL platelet-poor plasma after processing — follow laboratory minimum volume requirement
Timed relative to any recent factor replacement therapy; draw before infusion for trough levels or 15–30 min post-infusion for peak per haematology protocol; not affected by fasting
No fasting is required for Factor VIII activity testing
Double-centrifuge to platelet-poor plasma within 1 hour of collection; aliquot to plastic vial; freeze at −20 °C or colder per laboratory coagulation protocol when not immediately tested
Typically same-day in institutions with on-site coagulation testing; days for send-out laboratories — confirm with local lab
Coagulation / specialized haemostasis laboratory
What is Factor VIII Activity?
Factor VIII Activity is a one-stage or two-stage clotting assay that measures the functional activity of coagulation Factor VIII in plasma, expressed as a percentage of normal activity (100% = mean of healthy reference population). It is the primary diagnostic test for haemophilia A and is used to classify severity: severe (<1%), moderate (1–5%), and mild (>5–<40%) per World Federation of Hemophilia guidelines.
Overview
Nurses most often encounter Factor VIII activity testing in patients presenting with easy bruising, spontaneous or disproportionate bleeding, joint haemarthrosis, or a prolonged activated partial thromboplastin time (aPTT) with a normal prothrombin time (PT). It is also ordered to confirm a haemophilia A diagnosis in a patient with a known family history, to classify disease severity before surgery or invasive procedures, and to monitor factor replacement therapy peaks and troughs.
Von Willebrand disease (VWD) can cause secondarily low FVIII because von Willebrand factor stabilises Factor VIII in circulation — VWD type 2N in particular can mimic haemophilia A. A complete blood count (CBC) and coagulation screen including aPTT will often be ordered alongside FVIII. Nurses support accurate results through correct citrate collection technique, documentation of recent factor infusions, and rapid specimen processing.
Before collection, verify draw timing relative to any recent factor concentrate infusion (peak vs trough), ensure the citrate tube is filled exactly to the marked line and immediately inverted at least six times, and document current haematology plan and bleeding precautions. Escalate active joint swelling, uncontrolled gum bleeding, or trauma immediately — pending FVIII results do not delay haemostasis management. Never administer NSAIDs or IM injections without confirming haematology clearance for known or suspected haemophilia. Step-by-step citrate venipuncture technique is linked in the Performance — nursing procedure guide section on this page.
Haemophilia A Bleeding and Specimen Safety
Factor VIII Activity results guide haemophilia A severity classification and treatment monitoring, but nurses must act on bleeding signs immediately — never await a send-out result before escalating active haemarthrosis, internal bleeding, or head trauma. Citrate specimen quality directly determines result validity.
- Administering NSAIDs or IM injections without haematology clearance in a patient with known or suspected FVIII deficiency
- Active haemarthrosis, muscle haematoma, or trauma in a patient with low FVIII — escalate per facility protocol; do not defer for pending results
- Underfilled citrate tube or heparin-contaminated draw producing falsely low FVIII and triggering unnecessary intervention
- Misidentifying trough vs peak draw timing — misleads dosing decisions for factor concentrate therapy
Document: draw type (trough/peak/diagnostic), last factor concentrate or DDAVP dose and time, tube fill and processing, bleeding precaution status, result with reference interval, haematology notification, and near-miss medication interceptions.
What Factor VIII Activity Can and Cannot Tell You
This test can help identify:
- Haemophilia A severity (severe <1%, moderate 1–5%, mild 5–<40%) when appropriately timed and collected
- Inadequate trough levels between factor concentrate doses — guides dosing interval adjustments
- Subtherapeutic or supratherapeutic peak levels after infusion or DDAVP
- Possible FVIII inhibitor pattern (unexpectedly low activity despite adequate replacement) — triggers inhibitor screen
This test cannot:
- Distinguish hereditary haemophilia A from VWD type 2N or acquired FVIII inhibitor without additional testing (VWF assay, inhibitor titre)
- Replace clinical assessment — a patient with FVIII 8% and active joint swelling requires haematology escalation regardless of result timing
- Confirm haemostasis during acute bleeding — factor replacement decisions are based on clinical assessment and haematology protocol, not solely on a pending level
- Detect platelet function defects, fibrinogen abnormalities, or extrinsic pathway problems — those require separate testing
Citrate Collection Checks Before Factor VIII Draw
Verify
Clarify before proceeding when:
- Draw timing relative to last factor infusion is ambiguous — trough vs peak misidentification affects interpretation
- Patient is receiving emicizumab — FVIII one-stage assay may be spuriously elevated; chromogenic assay required per haematology
- Prior specimen rejected for underfill, haemolysis, or clot — review fill technique before repeat draw
- Active bleeding site is present — address haemostasis first, draw specimen second
- FVIII inhibitor is suspected — standard FVIII assay alone is insufficient; inhibitor screen and Bethesda assay needed
- Acute-phase illness, recent surgery, or pregnancy may transiently elevate FVIII and obscure mild haemophilia A
FVIII Percentage, Severity, and Acute Bleeding
Pair Factor VIII activity with aPTT, PT, platelet count, VWF antigen and activity, and FVIII inhibitor screen when clinical picture does not fit a simple haemophilia A pattern. One-stage and chromogenic assay results may diverge in specific haemophilia A variants; haematology determines which assay is primary for a given patient per Nordic and WFH guidelines.
| Clinical context | Pair with FVIII activity | Nursing focus |
|---|---|---|
| Isolated prolonged aPTT, normal PT | FVIII + FIX + FXI + mixing study | Hold invasive procedures; escalate to haematology for full panel interpretation |
| Low FVIII with high VWF antigen | VWF ristocetin cofactor and multimer analysis | Suggests VWD type 2N — different management from hereditary haemophilia A |
| Subtherapeutic trough on standard prophylaxis | FVIII inhibitor screen (Bethesda assay) | Escalate to haematology; inhibitor changes factor dosing strategy entirely |
| Emicizumab therapy (haemophilia A with inhibitor) | Chromogenic FVIII assay only — one-stage spuriously elevated | Confirm assay type with haematology before acting on a “normal” one-stage result |
On a small screen, swipe or scroll sideways to see the full table.
Factor VIII Results at the Bedside
| Bedside point | Nursing note |
|---|---|
| Trough vs peak confusion | Always document exact last dose time and draw time — mixing them up distorts dosing decisions for factor concentrate |
| NSAID alert | NSAIDs inhibit platelet function and worsen bleeding in all haemophilia A patients — intercept orders before administration |
| IM injection risk | Never administer IM injections without confirmed haematology clearance and documented FVIII activity target |
| Tube fill | Underfilled citrate is a frequent reject — fill exactly to the black marked line and mix gently ×6 |
| Emicizumab caution | One-stage FVIII assay is unreliable in patients on emicizumab — confirm assay method with haematology before acting on result |
| Head trauma escalation | Any head injury in a patient with haemophilia A requires immediate haematology and emergency review — do not observe and wait |
On a small screen, swipe or scroll sideways to see the full table.
Haemophilia Workup Workflow Integration
Diagnostic safety badge: Routine coagulation laboratory test — standard identification, preparation, and result-follow-up checks apply; low results require haematology review and active bleeding precautions.
Check-before-test protocol
- Identity + indication + trough or peak draw type confirmed
- Last factor concentrate or DDAVP dose and time documented on requisition
- Bleeding precautions active: NSAIDs and IM injections held
- Citrate tube fill-line and processing steps confirmed with laboratory
- Active bleeding site assessed — escalate before or instead of routine draw if acutely bleeding
Critical teach-back questions
- “Can you tell me which pain medicines are safe for you to take at home for joint pain?”
- “What symptoms would make you come to hospital immediately without waiting?”
- “Why is it important that we draw the blood sample at this specific time relative to your last factor injection?”
Care coordination: haematology, laboratory/coagulation services, pharmacy (NSAID/IM safety review), physiotherapy for joint rehabilitation, patient/family education team, and rapid response per institutional protocol.
Factor VIII Activity Quick Checklist
- Is this a trough or peak draw — and is the last dose time documented precisely?
- Is the citrate tube filled exactly to the marked line and processed within 1 hour?
- Are NSAIDs and IM injections held pending haematology clearance?
- Is there any active bleeding that needs escalation before or instead of the draw?
- Does a low or unexpected FVIII result require inhibitor screen and haematology notification?
- Has the patient and family received education on safe analgesics and bleeding warning signs?
Why Factor VIII Activity is Ordered
Factor VIII activity is ordered when a bleeding disorder affecting the intrinsic pathway is suspected, when haemophilia A is already diagnosed and severity or treatment monitoring is needed, or when a prolonged aPTT with normal PT requires explanation.
| Clinical Indication | What the Test Answers | Nursing Rationale |
|---|---|---|
| Diagnosis of haemophilia A or unexplained FVIII deficiency | Does the patient have a Factor VIII deficiency causing bleeding? | FVIII activity quantifies deficiency and classifies severity as severe (<1%), moderate (1–5%), or mild (>5–<40%) per WFH 2020 guidelines. |
| Isolated prolonged aPTT with normal PT and platelet count | Is an intrinsic pathway factor deficiency explaining the prolonged aPTT? | FVIII deficiency is a common cause of isolated aPTT prolongation; ordered together with FIX, FXI, and mixing studies to localise the defect. |
| Pre-operative assessment in known or suspected haemophilia A | Is FVIII activity adequate for the planned procedure, or is factor replacement needed? | Haematology uses perioperative FVIII targets (often ≥80–100% for major surgery) to guide prophylactic factor concentrate dosing per institutional protocol. |
| Monitoring factor VIII replacement therapy or desmopressin response | Has factor replacement or DDAVP raised FVIII activity to the target level? | Peak (15–30 min post-infusion) and trough (pre-dose) FVIII levels confirm therapeutic response and guide dosing adjustments per haematology protocol. |
Contraindications and Precautions
There is no absolute patient contraindication to a blood draw for FVIII, but specific pre-analytic conditions make results unreliable and require clarification before the specimen is sent.
- Underfilled citrate tube — alters blood-to-anticoagulant ratio and falsely prolongs clotting-based (one-stage) FVIII assay.
- Sample drawn from a heparin-contaminated line without appropriate flush discard — heparin prolongs aPTT-based assays and can produce falsely low FVIII.
- Specimen not processed promptly or left at room temperature — FVIII activity degrades; must reach platelet-poor plasma stage within 1 hour per coagulation handling protocol.
- Recent factor concentrate infusion or DDAVP — draw timing determines whether result reflects peak, trough, or intermediate level; document last dose and time.
- Acute phase reaction, pregnancy, or oral contraceptives — FVIII is an acute-phase reactant and may be transiently elevated, masking mild haemophilia A.
- von Willebrand factor deficiency (VWD type 2N/3) — low VWF leads to secondarily low FVIII; VWF antigen and ristocetin cofactor activity should accompany FVIII.
- Active joint swelling (haemarthrosis), muscle haematoma, or post-traumatic uncontrolled bleeding — escalate per haematology and facility protocol immediately.
- Signs of intracranial, retroperitoneal, or oropharyngeal bleeding in any patient with known or suspected FVIII deficiency — life-threatening haemorrhage pathway.
- FVIII activity confirmed severely low (<1%) in a patient without known haemophilia or with acquired inhibitor signs — notify haematology urgently per protocol.
Patient Preparation
No fasting is required. Preparation focuses on timing relative to recent factor infusions, confirming citrate tube availability and fill-line requirement, and reviewing bleeding-precaution status before the draw.
Pre-test checksReview current anticoagulants (heparin, DOACs, warfarin), recent factor VIII concentrate infusions, DDAVP (desmopressin), emicizumab, and any NSAIDs or antiplatelet agents. Do not stop prescribed haemophilia therapy without haematology authorization — document last dose and time on the requisition.
Performance — nursing procedure guide
This page is a Tests & Diagnostics guide for Factor VIII Activity. It emphasizes why the test is ordered, how to interpret results, when to escalate, and preparation factors that affect validity — not step-by-step performance technique (those live under Nursing Procedures when available).
Step-by-step technique, supplies, infection prevention, and immediate post-procedure monitoring for this test are covered in:
Use the Patient preparation, Results and interpretation, and Nursing responsibilities sections on this page for order verification, pre-analytic checks, result follow-up, critical-value escalation, and documentation.
Result follow-up at a glance
Nursing workflow on this page — from order to safe action on results:
Results and Interpretation
Factor VIII activity is reported as a percentage of normal (100% = mean healthy adult reference). Results below the laboratory reference interval indicate deficiency; severity classification — severe (<1%), moderate (1–5%), mild (>5% to <40%) — requires haematology interpretation in clinical context per WFH 2020 guidelines. Reference ranges and assay methods (one-stage vs chromogenic) vary between laboratories.
Reference ranges, critical values, and protocols may vary by laboratory, institution, patient population, and testing method. Always follow local policy and the reporting laboratory’s reference range.
| Result | Range / Finding | Clinical Meaning | Nursing Action |
|---|---|---|---|
| Within expected range or therapeutic target | Within institutional reference interval (FVIII activity %) | FVIII clotting activity adequate at time of sample | Interpret with aPTT and clinical presentation; transiently elevated FVIII in acute-phase states may mask mild haemophilia A — repeat per haematology if clinical suspicion remains |
| Near therapeutic target / borderline | Low-normal or borderline FVIII (e.g., 40–60%) | May reflect mild carrier state, VWD type 2N with low VWF, or transient suppression; one-stage vs chromogenic discordance possible | Repeat testing per haematology protocol; add VWF antigen and ristocetin cofactor; discuss with haematology before invasive procedures |
| Prolonged / above target | Elevated FVIII activity (>150–200%) | Not typically pathological; commonly seen as acute-phase response, pregnancy, OCP use, or recent factor infusion — not a haemostasis escalation trigger alone | Interpret with clinical context; note timing of factor infusions; no routine escalation unless thrombotic risk is suspected in specific high-risk populations |
| Shortened / below target | Below reference interval (decreased FVIII activity) | Consistent with haemophilia A (inherited) or acquired FVIII inhibitor; secondary low FVIII from VWD type 2N/3; severity classified by percentage per WFH criteria | Notify haematology; apply or confirm bleeding precautions; hold NSAIDs and IM injections; arrange FVIII inhibitor screen and VWF testing if not already ordered; escalate active bleeding immediately |
Protocol targets, critical results and escalation
Universal numeric critical values for FVIII activity are not published as a single standard threshold in the published references. Escalation is driven by severity of deficiency in clinical context, active bleeding, and haematology protocol — not by a single number. Reference intervals and critical call thresholds vary by laboratory and institutional policy.
| Critical Finding | Threshold / Value | Immediate Action |
|---|---|---|
| Severe FVIII deficiency with active bleeding or trauma | Very low or undetectable FVIII activity with clinical bleed | Escalate per haematology and facility protocol; initiate factor replacement or haemostasis pathway; do not defer for pending results in active haemorrhage |
| Suspected acquired FVIII inhibitor | New or worsening FVIII deficiency without hereditary history | Notify haematology urgently; FVIII inhibitor titre (Bethesda assay) and immune workup required; factor concentrate dosing differs from hereditary haemophilia |
| Pre-operative FVIII below target | FVIII below haematology-set target before planned surgery or procedure | Contact haematology and surgical/procedural team immediately; do not proceed without documented haematology clearance and factor replacement plan |
Stop routine workflow and escalate according to facility policy when a patient with known or suspected FVIII deficiency develops active joint swelling, uncontrolled bleeding at any site, or signs of intracranial or internal haemorrhage — pending FVIII results do not delay emergency haemostasis management.
Factors Affecting Results
Factor VIII activity assays are sensitive to specimen quality and clinical timing. Nurses prevent misinterpretation by correct citrate technique, prompt processing, and accurate documentation of infusion timing and bleeding-risk medications.
- Falsely low FVIII from underfilled citrate tube or delayed processing beyond 1 hour at room temperature
- Heparin contamination from line draw without adequate discard or flush hold — interferes with one-stage aPTT-based FVIII assay
- FVIII inhibitor (antibody) in sample — mixing study and Bethesda titre needed to differentiate from simple deficiency
- Falsely normal or elevated FVIII during acute illness, surgery, pregnancy, or shortly after factor infusion — masking mild haemophilia A
- One-stage vs chromogenic discordance — some mild haemophilia A variants give normal one-stage but low chromogenic activity; both methods may be needed
- Assuming a normal FVIII rules out all bleeding disorders — VWD, platelet defects, and other factor deficiencies may coexist with normal FVIII
- Timing relative to factor concentrate or DDAVP infusion (peak vs trough)
- Acute-phase elevation from infection, inflammation, surgery, or pregnancy
- Specimen quality — underfill, haemolysis, delayed processing, or heparin contamination
Factor VIII activity does not diagnose the cause of deficiency alone — hereditary haemophilia A, VWD type 2N, and acquired inhibitors all produce low FVIII and require additional testing. One-stage assay results may diverge from chromogenic assay in specific haemophilia A variants, influencing dosing and treatment decisions per Nordic and WFH guidelines. Reference intervals and critical call thresholds differ between laboratories and clinical contexts.
Nursing Responsibilities
Nursing responsibilities emphasise correct coagulation specimen handling, bleeding precaution monitoring, medication safety (no NSAIDs or IM injections without haematology clearance), and clear communication of low or critical FVIII values.
Before the TestDocumentation
Documentation must link specimen quality, infusion timing, clinical bleeding status, and communication of abnormal results to haematology and the care team.
“Factor VIII activity specimen collected 10:15 — light-blue citrate tube filled to line, inverted ×6, double-spun per coagulation protocol, frozen aliquot sent to haemostasis laboratory. Trough draw: last factor VIII concentrate 09:30 prior day per haematology order. No active joint swelling today; right knee redness noted in morning assessment — haematology notified at 10:30. NSAIDs withheld per bleeding precaution plan. Result pending; patient advised to report any new joint pain or swelling.”
- Indication, draw type (trough/peak/diagnostic), and haematology protocol met
- Tube type, fill level, mixing, centrifuge steps, and transport compliance
- Last factor concentrate or DDAVP dose, time, and route
- Result value with laboratory reference interval and severity classification
- Haematology notification, bleeding precautions confirmed, NSAIDs/IM status
- Any active bleeding episode, site assessment, and escalation pathway initiated
Patient and Family Education
Patients with haemophilia A and their families need clear, practical information about what the test means and what bleeding warning signs require urgent review.
Factor VIII Activity NCLEX practice questions
Practice NCLEX-style clinical judgment focused on Factor VIII Activity safety and nursing judgment. Use the case tabs (orders, results, assessment, nursing notes), then answer eight Next Gen–style items (including an ordered workflow step) and evaluate outcomes with the answer key.
Select a tab to view orders, results, assessment, and nursing note details for this case.
- Order: Factor VIII activity (one-stage) — plasma, coagulation panel
- Indication: 16-year-old male presenting with right knee haemarthrosis after minor sports impact; known haemophilia A, last FVIII concentrate 36 hours ago
- Timing: Trough draw ordered before next scheduled factor concentrate dose
- Related orders: aPTT, prothrombin time (PT), CBC with differential; haematology consulted; ibuprofen held per nursing assessment note
- Result: FVIII activity 8% (mild–moderate range; laboratory reference >50%); aPTT 62 seconds (prolonged); PT 13 s (normal); platelets 224 × 10⁹/L (normal)
- Trend / prior value: FVIII 8% today vs 42% measured 4 hours post-infusion on prior admission — trough below expected; haematology reviewing dosing interval
- Pending tests: Haematology review of dosing protocol; FVIII inhibitor screen ordered; next factor concentrate dose pending haematology confirmation
- Vital signs: HR 102/min, BP 108/68, RR 18/min, SpO₂ 99% on room air, Temp 37.1 °C; pain 7/10 right knee
- Symptoms: Right knee visibly swollen, warm, and tender; reports taking ibuprofen at home for knee pain before presenting; no headache, vision change, or abdominal pain
- Focused assessment: Right knee circumference 4 cm greater than left; range of motion limited by pain; no skin laceration; no other joint swelling; capillary refill <2 s bilaterally
- Preparation notes: Trough draw documented; citrate tube filled to line and inverted ×6; ibuprofen withheld after nursing review — near-miss IM ketorolac order identified and held pending haematology clearance
- Collection events: Near-miss: ketorolac IM order entered by on-call provider; nurse held and escalated to haematology before administration; ibuprofen use at home documented on admission — patient family not aware NSAIDs are contraindicated
- Teaching gaps / safety concerns: FVIII trough 8% with active haemarthrosis; NSAID use at home; near-miss IM ketorolac; dosing interval under review; inhibitor screen pending; patient and family education gap on medication safety
Answer key & rationale
Frequently Asked Questions
FAQ
What does Factor VIII activity percentage mean?
It shows how much clotting function Factor VIII is providing compared with a healthy reference population (100% = full activity). Haemophilia A is classified as severe when FVIII is less than 1%, moderate between 1–5%, and mild between 5–40% per World Federation of Hemophilia 2020 guidelines. Results vary between laboratories and assay methods — always interpret with the local reference interval.
Why does Factor VIII activity use a light-blue tube?
The light-blue tube contains 3.2% sodium citrate, which binds calcium to reversibly stop coagulation in the sample. The clotting assay is then reactivated in the laboratory to measure how quickly and completely Factor VIII supports clot formation. Underfilling the tube alters the citrate-to-blood ratio and can falsely prolong results — fill to the marked line exactly.
Can Factor VIII activity be drawn from a heparin line?
Heparin contamination from vascular access devices prolongs the aPTT-based one-stage assay and can produce falsely low FVIII activity. Confirm institutional policy: many laboratories require a clean peripheral venepuncture or a specific discard volume from the line. Document the draw site and any flush or discard procedure used.
Why can’t the patient take ibuprofen for joint pain?
NSAIDs inhibit platelet aggregation via cyclooxygenase inhibition, which increases bleeding risk in haemophilia A even when factor concentrate is being given. Paracetamol (acetaminophen) is generally the recommended analgesic for patients with haemophilia — confirm with haematology for each patient.
What is the difference between a trough and a peak FVIII draw?
A trough draw is taken immediately before the next scheduled factor concentrate dose to verify that FVIII activity has not fallen below the haematology-set minimum. A peak draw is taken approximately 15–30 minutes post-infusion to confirm the expected activity rise. Document the last dose time and draw time precisely — misidentifying trough vs peak misleads dosing decisions.
What is an acquired FVIII inhibitor and why does it matter?
An acquired FVIII inhibitor is an antibody that neutralises Factor VIII, causing unexpectedly low activity despite replacement therapy. It can occur in hereditary haemophilia A (alloantibody after factor exposure) or as an acquired autoantibody in previously healthy individuals. The Bethesda assay quantifies inhibitor titre. Management differs substantially from inhibitor-free haemophilia and requires specialist haematology input.
When should the nurse escalate before the FVIII result returns?
Escalate according to facility policy if the patient develops new or worsening joint swelling, muscle haematoma, prolonged bleeding from any site, headache or neurological change after trauma, neck stiffness, groin pain, or any symptom suggesting internal bleeding — pending FVIII results do not delay haemostasis management.
References
References
-
MedlinePlus. Factor VIII Activity. Bethesda (MD): U.S. National Library of Medicine.https://medlineplus.gov/lab-tests/factor-viii-activity/
-
Labcorp. Factor VIII Activity — Test 116400. Burlington (NC): Labcorp.https://www.labcorp.com/tests/116400/factor-viii-activity
-
Srivastava A; et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. World Federation of Hemophilia.https://onlinelibrary.wiley.com/doi/10.1111/hae.14046
-
Boender J; Lenting PJ; Schutgens REG. Measurement of FVIII and FIX levels: one-stage vs chromogenic assays. Thromb Res. 2021. PMC review on FVIII/IX measurement.https://pmc.ncbi.nlm.nih.gov/articles/PMC7116012/
-
Berntorp E; et al. Haemophilia A and B treatment guidelines. Nordic Hemophilia Council. 2020.https://www.nordichemophilia.org/
-
Centers for Disease Control and Prevention. Hemophilia — Diagnosis and Types. Atlanta (GA): CDC.https://www.cdc.gov/hemophilia/about/index.html
-
Konkle BA; Nakaya Fletcher S. Hemophilia A. GeneReviews® [Internet]. Seattle (WA): University of Washington; 2000 (updated 2023).https://www.ncbi.nlm.nih.gov/books/NBK1404/
-
Mancuso ME; Santagostino E. Outcome of Clinical Trials with New Extended Half-Life FVIII/IX Concentrates. J Clin Med. 2017;6(4):39. StatPearls supplementary — haemophilia A pharmacology.https://pmc.ncbi.nlm.nih.gov/articles/PMC5406785/
Editorial Standards & Medical Review
About the author: Sid A. Abdala Balal, RN, writes evidence-based nursing education focused on diagnostic safety, clinical interpretation, and bedside nursing judgment.
Medical review: This guide is reviewed by Dr. Adam Sayedi, MD, for clinical accuracy, diagnostic safety, and alignment with current standards for Factor VIII Activity.
Policies: Medical Review Process · Editorial Policy · Correction Policy